Non-Hodgkin's lymphoma

13 trials 5 recruiting MedDRA PT
13 Registered trials
5 Recruiting
13 Unique sponsors
13 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 2
J Anti-infectives (ATC J) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Monoclonal antibody (chimeric) 1 substance
BCL-2 inhibitor 1 substance
Immunoglobulin 1 substance
BTK inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Phase III: 2 Phase II: 2 Phase I/II: 4 Phase I: 1 Phase I (Other): 2 Phase I (First in Human): 2

Filter these 13 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 13 trials

Phase III

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    VENETOCLAX
    2022-501522-38-00 7 countries 2020 n=29
    Ended
  • Grifols Therapeutics LLC Commercial
    HUMAN NORMAL IMMUNOGLOBULIN
    2022-502193-16-00 5 countries 2023 n=94
    Recruiting

Phase II

2 trials
  • Autolus Limited Commercial
    AUTO4; AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD22; RITUXIMAB
    2024-511684-28-00 1 country 2025 n=21 Orphan
    Recruiting
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    BRENTUXIMAB VEDOTIN
    2023-510556-22-00 3 countries 2018 n=36
    Ended

Phase I/II

4 trials
  • Cellcentric Limited Commercial
    INOBRODIB
    2024-519498-20-00 1 country 2025 n=16
    Recruiting
  • Epizyme Inc. Commercial
    TAZEMETOSTAT
    2023-510553-41-00 2 countries 2016 n=40
    Ended
  • Merck Sharp & Dohme LLC Commercial
    MK-1045
    2025-523005-15-00 5 countries n=73
    Pending
  • Klinikum rechts der Isar der TU Muenchen AöR Academic
    GALLIUM (68GA), PENTIXAFOR; PENTIXATHER, YTTRIUM-90
    2024-517639-35-00 1 country n=38
    Pending

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended

Phase I (Other)

2 trials
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-520222-11-00 3 countries 2026 n=15
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-514176-41-00 1 country 2024 n=16
    Ended

Phase I (First in Human)

2 trials
  • Enterome Commercial
    UCP2, OMP72, OMP64, OMP65, OMP66
    2023-509254-58-00 3 countries 2021 n=29
    Recruiting
  • Loxo Oncology Inc. Commercial
    PIRTOBRUTINIB
    2023-509270-37-00 3 countries 2019 n=37
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 1 Phase I 0
Century Therapeutics Inc. Commercial 1 Phase I (Other) 1
Janssen - Cilag International Commercial 1 Phase I (Other) 0
Autolus Limited Commercial 1 Phase II 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase III 0
Grifols Therapeutics LLC Commercial 1 Phase III 1
Enterome Commercial 1 Phase I (First in Human) 1
Loxo Oncology Inc. Commercial 1 Phase I (First in Human) 0
Cellcentric Limited Commercial 1 Phase I/II 1
Epizyme Inc. Commercial 1 Phase I/II 0
Merck Sharp & Dohme LLC Commercial 1 Phase I/II 0
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic 1 Phase II 0
Klinikum rechts der Isar der TU Muenchen AöR Academic 1 Phase I/II 0
New trials by year
2019
1
2020
1
2021
1
2023
1
2024
2
2025
2
2026
1
← All indication landscapes